4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
4D Molecular Therapeutics (FDMT) has announced its participation in multiple upcoming investor conferences and the Ophthalmology Innovation Summit XIV. The company will engage in fireside chats at the Jefferies London Healthcare Conference on November 19, 2024 (12:00 p.m. GMT) and the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024 (1:45 p.m. ET). Additionally, Dr. Carlos Quezada-Ruiz will present at the Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase on November 22, 2024 (4:40 p.m. PT). Webcasts will be available for up to one year on the company's investor relations website.
4D Molecular Therapeutics (FDMT) ha annunciato la sua partecipazione a molteplici conferenze per investitori imminenti e al XIV Summit sull'Innovazione in Oftalmologia. L'azienda parteciperà a conversazioni informali durante la Jefferies London Healthcare Conference il 19 novembre 2024 (ore 12:00 GMT) e la 7ª Conferenza Annuale Evercore ISI HealthCONx il 3 dicembre 2024 (ore 13:45 ET). Inoltre, il Dr. Carlos Quezada-Ruiz presenterà al Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase il 22 novembre 2024 (ore 16:40 PT). Le registrazioni web saranno disponibili fino a un anno sul sito web per le relazioni con gli investitori dell'azienda.
4D Molecular Therapeutics (FDMT) ha anunciado su participación en varias conferencias de inversores próximas y en la XIV Cumbre de Innovación en Oftalmología. La compañía participará en charlas informales en la Jefferies London Healthcare Conference el 19 de noviembre de 2024 (12:00 p.m. GMT) y en la 7ª Conferencia Anual Evercore ISI HealthCONx el 3 de diciembre de 2024 (1:45 p.m. ET). Además, el Dr. Carlos Quezada-Ruiz presentará en la Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase el 22 de noviembre de 2024 (4:40 p.m. PT). Las retransmisiones estarán disponibles durante hasta un año en el sitio web de relaciones con inversores de la empresa.
4D Molecular Therapeutics (FDMT)는 다가오는 여러 투자자 회의와 제14회 안과 혁신 서밋에 참석한다고 발표했습니다. 이 회사는 Jefferies London Healthcare Conference에서 2024년 11월 19일(오후 12:00 GMT)과 7번째 연례 Evercore ISI HealthCONx Conference에서 2024년 12월 3일(오후 1:45 ET)에 파이어사이드 챗에 참여할 것입니다. 또한, Carlos Quezada-Ruiz 박사는 2024년 11월 22일(오후 4:40 PT)에 Ophthalmology Innovation Summit XIV 유전자 및 세포 치료 쇼케이스에서 발표할 것입니다. 웹캐스트는 회사의 투자자 관계 웹사이트에서 최대 1년 동안 이용 가능합니다.
4D Molecular Therapeutics (FDMT) a annoncé sa participation à plusieurs conférences pour investisseurs à venir et au XIVe Sommet de l'Innovation en Ophtalmologie. La société participera à des discussions informelles lors de la Jefferies London Healthcare Conference le 19 novembre 2024 (12h00 GMT) et de la 7ème Conférence Annuelle Evercore ISI HealthCONx le 3 décembre 2024 (13h45 ET). De plus, le Dr Carlos Quezada-Ruiz présentera lors de la Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase le 22 novembre 2024 (16h40 PT). Des webinaires seront disponibles pendant jusqu'à un an sur le site des relations investisseurs de la société.
4D Molecular Therapeutics (FDMT) hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen und dem XIV. Innovationsgipfel für Augenheilkunde bekannt gegeben. Das Unternehmen wird am 19. November 2024 (12:00 Uhr GMT) an informellen Gesprächen auf der Jefferies London Healthcare Conference und am 3. Dezember 2024 (13:45 Uhr ET) auf der 7. Jahrestagung Evercore ISI HealthCONx Conference teilnehmen. Darüber hinaus wird Dr. Carlos Quezada-Ruiz am 22. November 2024 (16:40 Uhr PT) auf der Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase präsentieren. Webcasts werden bis zu einem Jahr auf der Investor Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in November and December and will present at the Ophthalmology Innovation Summit XIV. Members of the management team will also be available for one-on-one meetings at the respective investor conferences.
Jefferies London Healthcare Conference 2024
| Presentation Date: | Tuesday, November 19, 2024 |
| Presentation Time: | 12:00 p.m. GMT |
| Webcast Link: | Webcast |
7th Annual Evercore ISI HealthCONx Conference
| Presentation Date: | Tuesday, December 3, 2024 |
| Presentation Time: | 1:45 p.m. ET |
| Webcast Link: | Webcast |
Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
Ophthalmology Innovation Summit XIV
| Session Title: | Gene & Cell Therapy Showcase |
| Presenter: | Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology |
| Presentation Date: | Friday, November 22, 2024 |
| Presentation Time: | 4:40 p.m. PT |
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine Smith
Inizio Evoke Comms
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is 4DMT (FDMT) presenting at the Jefferies London Healthcare Conference 2024?
What conferences will 4DMT (FDMT) attend in November and December 2024?
Who will represent 4DMT (FDMT) at the Ophthalmology Innovation Summit XIV?
How long will the 4DMT (FDMT) conference webcasts be available?
